Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107078 | 1.00 | DRD2 (0.46) | DRD2DRD3FAAHIDH1KMT2A | |
| SCHEMBL923515 | 0.89 | FAAH (0.42) | DRD2DRD3FAAHIDH1KCNMA1 | |
| SCHEMBL3233785 | 0.87 | KMT2A (0.44) | DRD2DRD3FAAHIDH1KMT2A | |
| SCHEMBL2878655 | 0.85 | DRD2 (0.49) | DRD2DRD3KMT2AKDM4E | |
| SCHEMBL3657710 | 0.82 | DRD2 (0.47) | DRD2DRD3FAAHIDH1KDM4E | |
| SCHEMBL3657715 | 0.82 | DRD2 (0.47) | DRD2DRD3FAAHIDH1KDM4E | |
| SCHEMBL3659200 | 0.82 | DRD2 (0.47) | DRD2DRD3FAAHIDH1KDM4E | |
| SCHEMBL21465763 | 0.81 | DRD2 (0.46) | DRD2DRD3FAAHIDH1KMT2A | |
| SCHEMBL30894461 | 0.81 | DRD2 (0.46) | DRD2DRD3FAAHIDH1KMT2A | |
| SCHEMBL4432302 | 0.79 | MTNR1A (0.53) | FAAHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-8153651-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2012-04-10 | — | — | US | disclosed |
| EP-2215054-B8 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2215054-B1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-7135570-B2 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2006-11-14 | — | — | US | disclosed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | DRD2 1371/4885DRD3 1315/4885FAAH 1144/4885 |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | DRD2 1371/4885DRD3 1315/4885FAAH 1144/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | DRD2 1371/4885DRD3 1315/4885FAAH 1144/4885 |
| US-20110021514-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | DRD2 2779/4885DRD3 2969/4885FAAH 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.